Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay.
Int J Tuberc Lung Dis
; 23(3): 358-362, 2019 03 01.
Article
en En
| MEDLINE
| ID: mdl-30940300
ABSTRACT
SETTING:
Xpert® MTB/RIF is the first-line diagnostic test for Mycobacterium tuberculosis and rifampicin (RIF) resistance in South Africa.OBJECTIVE:
To describe the rates of Xpert RIF resistance not confirmed on follow-up testing, as well as the patient and test characteristics associated with discordant results.DESIGN:
Retrospective review of patients with isolates showing Xpert RIF resistance. Line-probe assay, phenotypic drug susceptibility testing or repeat Xpert were all considered confirmatory tests of RIF resistance. 'Discordance' was defined as a patient with RIF resistance identified on initial Xpert testing, with a subsequent confirmatory test indicating RIF susceptibility. Associations were analysed using Pearson χ² difference of proportions and modified Poisson regression.RESULTS:
RIF discordance occurred in 22/263 subjects and was associated with Xpert probe B, probe binding delay, as opposed to probe dropout, and probe binding delays (ΔCt) of between 4 and 4.9.CONCLUSION:
Discordant RIF resistance was common in our cohort and was associated with Xpert probe delay and use of probe B.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Rifampin
/
Tuberculosis
/
Antibióticos Antituberculosos
/
Mycobacterium tuberculosis
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
País/Región como asunto:
Africa
Idioma:
En
Revista:
Int J Tuberc Lung Dis
Año:
2019
Tipo del documento:
Article